

FANCL Antibody(C-term) Blocking peptide
Synthetic peptide
Catalog # BP19508b**Specification**

FANCL Antibody(C-term) Blocking peptide - Product InformationPrimary Accession [Q9NW38](#)**FANCL Antibody(C-term) Blocking peptide - Additional Information****Gene ID** 55120**Other Names**

E3 ubiquitin-protein ligase FANCL, 632-, Fanconi anemia group L protein, Fanconi anemia-associated polypeptide of 43 kDa, FAAP43, FANCL, PHF9

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

FANCL Antibody(C-term) Blocking peptide - Protein Information**Name** FANCL**Synonyms** PHF9**Function**

Ubiquitin ligase protein that mediates monoubiquitination of FANCD2 in the presence of UBE2T, a key step in the DNA damage pathway (PubMed:12973351, PubMed:16916645, PubMed:17938197, PubMed:19111657, PubMed:24389026). Also mediates monoubiquitination of FANCI (PubMed:19589784). May stimulate the ubiquitin release from UBE2W. May be required for proper primordial germ cell proliferation in the embryonic stage, whereas it is probably not needed for spermatogonial proliferation after birth.

Cellular Location

Cytoplasm {ECO:0000250|UniProtKB:Q9CR14}. Nucleus {ECO:0000250|UniProtKB:Q9CR14}

FANCL Antibody(C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

FANCL Antibody(C-term) Blocking peptide - Images

FANCL Antibody(C-term) Blocking peptide - Background

The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconianemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group L. Alternative splicing results in two transcript variants encoding different isoforms.

FANCL Antibody(C-term) Blocking peptide - References

Zhang, J., et al. J. Clin. Invest. 120(5):1524-1534(2010) Garcia, M.J., et al. Carcinogenesis 30(11):1898-1902(2009) McWilliams, R.R., et al. Cancer Epidemiol. Biomarkers Prev. 18(9):2549-2552(2009) Longerich, S., et al. J. Biol. Chem. 284(35):23182-23186(2009) Hess, C.J., et al. Cell. Oncol. 30(4):299-306(2008)